109 related articles for article (PubMed ID: 3909804)
1. Phase II trial of methylglyoxal-bis-guanylhydrazone (methyl-GAG) in patients with soft-tissue sarcomas.
Sordillo PP; Magill GB; Welt S
Am J Clin Oncol; 1985 Aug; 8(4):316-8. PubMed ID: 3909804
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study.
Winter JN; Ritch PS; Rosen ST; Oken MM; Wolter JM; Wiernik PH; O'Connell MJ
Cancer Invest; 1990; 8(2):143-6. PubMed ID: 2205334
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
Amato DA; Borden EC; Shiraki M; Enterline HT; Rosenbaum C; Davis HL; Paul AR; Stevens CM; Lerner HJ
Invest New Drugs; 1985; 3(4):397-401. PubMed ID: 2417985
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of methyl-GAG (methylglyoxal-bis[guanylhydrazone]) in patients with advanced malignant lymphoma.
Warrell RP; Lee BJ; Kempin SJ; Lacher MJ; Straus DJ; Young CW
Blood; 1981 Jun; 57(6):1011-4. PubMed ID: 7013854
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma.
Fuks JZ; Van Echo DA; Aisner J; Mitchell EP; Woolley PV; Wiernik PH
Cancer Clin Trials; 1981; 4(4):411-4. PubMed ID: 7318123
[TBL] [Abstract][Full Text] [Related]
6. Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease. A Phase II trial of the Southwest Oncology Group.
Knight WA; Fabian C; Costanzi JJ; Jones SE; Coltman CA
Invest New Drugs; 1983; 1(3):235-7. PubMed ID: 6678871
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer.
Chapman R; Kelsen D; Gralla R; Itri L; Casper E; Young C; Golbey R
Cancer Clin Trials; 1981; 4(4):389-91. PubMed ID: 6274532
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
Bull FE; Von Hoff DD; Balcerzak SP; Stephens RL; Panettiere FJ
Cancer Treat Rep; 1985 Feb; 69(2):231-3. PubMed ID: 3882233
[No Abstract] [Full Text] [Related]
9. Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in advanced breast cancer. A Phase II trial of the Southwest Oncology Group.
Knight WA; O'Bryan RM; Samal B; Costanzi JJ
Invest New Drugs; 1984; 2(1):71-3. PubMed ID: 6469501
[TBL] [Abstract][Full Text] [Related]
10. Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate.
Scher HI; Yagoda A; Ahmed T; Watson RC
J Clin Oncol; 1985 Feb; 3(2):224-8. PubMed ID: 3968552
[TBL] [Abstract][Full Text] [Related]
11. Phase II trials of methylglyoxal-bis (guanylhydrazone).
Kelsen DP; Yagoda A; Warrell R; Chapman R; Whittes R; Gralla RJ; Casper E; Young CW
Am J Clin Oncol; 1982 Apr; 5(2):221-5. PubMed ID: 7046414
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of methyl-glyoxal bis-guanylhydrazone (NSC 3296) in advanced ovarian cancer.
Vogl SE; Pagano M; Horton J
Am J Clin Oncol; 1984 Dec; 7(6):733-6. PubMed ID: 6528867
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
Steward WP; Mouridsen HT; Kerbrat P; Somers R; Verweij J; Van Oosterom AT; Blackledge G; Havsteen H; Thomas D; Sylvester R
Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1251-3. PubMed ID: 2767113
[No Abstract] [Full Text] [Related]
14. Inefficacy of methylglyoxal bis(guanylhydrazone) (MGBG) in patients with recurrent head and neck squamous cell carcinoma.
Arteaga CL; Clark GM
Invest New Drugs; 1989 Jul; 7(2-3):281-3. PubMed ID: 2793385
[No Abstract] [Full Text] [Related]
15. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of echinomycin in advanced soft tissue sarcomas. A Southwest Oncology Group study.
Taylor SA; Metch B; Balcerzak SP; Hanson KH
Invest New Drugs; 1990 Nov; 8(4):381-3. PubMed ID: 2084072
[TBL] [Abstract][Full Text] [Related]
17. Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)].
Warrell RP; Coonley CJ; Burchenal JH
Cancer Chemother Pharmacol; 1983; 11(2):134-6. PubMed ID: 6414731
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of methyl-GAG in the treatment of esophageal carcinoma.
Kelsen D; Chapman R; Bains M; Heelan R; Dukeman M; Golbey R
Cancer Treat Rep; 1982 Jun; 66(6):1427-9. PubMed ID: 7083245
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Verweij J; Krzemieniecki K; Kok T; Poveda A; van Pottelsberghe C; van Glabbeke M; Mouridsen H
Eur J Cancer; 1993; 29A(2):208-9. PubMed ID: 8422284
[TBL] [Abstract][Full Text] [Related]
20. [Mitoguazone (methylglyoxal bis(guanylhydrazone))--its status and prospects].
Hoffmann H; Gutsche W; Amlacher R; Schulze W; Werner W; Lenk H; Wohlrab W; Haupt E
Arch Geschwulstforsch; 1989; 59(2):135-48. PubMed ID: 2655552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
